This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letter to the Editor

Hypotension Secondary to the Combination of Intramuscular Olanzapine and Intramuscular Lorazepam

Jennifer L. Zacher, PharmD, and Jennifer Roche-Desilets, PharmD, BCPS

Published: December 15, 2005

Article Abstract

Because this piece has no abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: An intramuscular (IM) formulation of olanzapine wasapproved by the U.S. Food and Drug Administration (FDA) inMarch 2004 for the treatment of agitation associated withschizophrenia and bipolar I disorder.1 The package insert for IMolanzapine reports significant incidence of orthostatic hypotensionin one third of nonagitated patients with schizophrenia whowere treated with the maximum recommended dosage of olanzapineIM (three 10-mg doses administered 4 hours apart).1Forty-nine adverse events, 29 of which were deemed seriousand 8, fatal, were reported in Europe.2‘ ‹

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 66

Quick Links: